Celcuity (NASDAQ: CELC) is one of 23 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its competitors? We will compare Celcuity to related companies based on the strength of its institutional ownership, valuation, profitability, analyst recommendations, risk, earnings and dividends.
Institutional & Insider Ownership
15.2% of Celcuity shares are held by institutional investors. Comparatively, 50.1% of shares of all “Medical laboratories” companies are held by institutional investors. 43.5% of Celcuity shares are held by insiders. Comparatively, 16.6% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Celcuity has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Celcuity’s competitors have a beta of 1.33, indicating that their average share price is 33% more volatile than the S&P 500.
This table compares Celcuity and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Celcuity and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||427.79|
Celcuity’s competitors have higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current ratings and target prices for Celcuity and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity currently has a consensus price target of $35.50, indicating a potential upside of 48.35%. As a group, “Medical laboratories” companies have a potential upside of 16.62%. Given Celcuity’s stronger consensus rating and higher probable upside, equities analysts clearly believe Celcuity is more favorable than its competitors.
Celcuity beats its competitors on 7 of the 13 factors compared.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.